Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- β-Thalassemias.N Engl J Med. 2021; 384: 727-743
- The inherited diseases of hemoglobin are an emerging global health burden.Blood. 2010; 115: 4331-4336
- Hematopoietic stem cell transplantation in thalassemia.Hematol Oncol Clin North Am. 2018; 32: 317-328
- Gene therapy for hemoglobinopathies: beta-thalassemia, sickle cell disease.Hematol Oncol Clin North Am. 2022; 36: 769-795
- Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.Blood. 2019; 134: 1203-1213
- Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives.EMBO Mol Med. 2019; 11https://doi.org/10.15252/emmm.201809958
- a nontoxic transduction enhancer enables highly efficient lentiviral transduction of primary murine T cells and hematopoietic stem cells.Mol Ther Methods Clin Dev. 2018; 10: 341-347
- Improving lentiviral transduction of CD34.Hum Gene Ther Methods. 2018; 29: 104-113
- Betibeglogene autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia.N Engl J Med. 2022; 386: 415-427
- Long-term outcomes of lentiviral gene therapy for the beta-hemoglobinopathies: the HGB-205 trial.Nat Med. 2022; 28: 81-88
- Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene.Hum Gene Ther. 2016; 27: 148-165
- Correction of sickle cell disease in transgenic mouse models by gene therapy.Science. 2001; 294: 2368-2371
- Gene therapy in patients with transfusion-dependent β-thalassemia.N Engl J Med. 2018; 378: 1479-1493
- Biologic and clinical efficacy of lentiglobin for sickle cell disease.N Engl J Med. 2022; 386: 617-628
- Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.Nat Med. 2019; 25: 234-241
- Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.Nat Med. 2022; 28: 63-70
- New Gene Therapy for β-Thalassemia.JAMA. 2022; 328: 1030
- Construction and evaluation of zinc finger nucleases.Methods Mol Biol. 2017; 1630: 1-24
- Genome engineering using TALENs.Methods Mol Biol. 2019; 1900: 195-215
- Genome editing. The new frontier of genome engineering with CRISPR-Cas9.Science. 2014; 346: 1258096
- The promise and challenge of therapeutic genome editing.Nature. 2020; 578: 229-236
- Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.Nat Med. 2021; 27: 677-687
- Molecular basis of hereditary persistence of fetal hemoglobin.Ann N Y Acad Sci. 1998; 850: 38-44
- Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies.Br J Haematol. 2018; 180: 630-643
- Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.Nat Genet. 2018; 50: 498-503
- Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.Science. 2016; 351: 285-289
- CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia.N Engl J Med. 2021; 384: 252-260
- Efficacy and safety of a single dose of CTX for transfusion-dependent beta-thalassemia and severe sickle cell disease.HemaSphere. 2022; 6: S3
- CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia.Nat Med. 2022; 28: 1573-1580
- Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia.Blood. 2021; 138: 3974
- Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.Blood Adv. 2019; 3: 3379-3392
- Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.Sci Adv. 2020; 6https://doi.org/10.1126/sciadv.aay9392
- Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.Sci Transl Med. 2019; 11https://doi.org/10.1126/scitranslmed.aaw3768
- A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Nat Med. 2016; 22: 987-990
- Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.Proc Natl Acad Sci U S A. 2016; 113: 10661-10665
- TALEN-Mediated Gene Editing of.Mol Ther Methods Clin Dev. 2019; 12: 175-183
- LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis.Dev Cell. 2009; 17: 527-540
- Programmable base editing of A• T to G• C in genomic DNA without DNA cleavage.Nature. 2017; 551: 464-471
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.Nature. 2016; 533: 420-424
- Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.Nat Biotechnol. 2020; 38: 824-844
- Base and Prime Editing Technologies for Blood Disorders.Front Genome Ed. 2021; 3: 618406
- Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies.Cell Res. 2020; 30: 276-278
- In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.Blood Adv. 2021; 5: 1122-1135
- Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.Elife. 2022; 11https://doi.org/10.7554/eLife.65421
- Base-editing-mediated dissection of a gamma-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression.Nat Commun. 2022; 13: 6618
- Therapy-related myelodysplasia and acute myeloid leukemia.Semin Oncol. 2013; 40: 666-675
- Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.Mol Ther. 2014; 22: 774-785
- Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.Hum Gene Ther. 2006; 17: 253-263
- Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia.Nature. 2010; 467: 318-322
- 3' UTR-truncated HMGA2 overexpression induces non-malignant in vivo expansion of hematopoietic stem cells in non-human primates.Mol Ther Methods Clin Dev. 2021; 21: 693-701
- Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.Blood Adv. 2020; 4: 2058-2063
- Acute myeloid leukemia case after gene therapy for sickle cell disease.N Engl J Med. 2022; 386: 138-147
- Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.Blood. 2021; 138: 942-947
- Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia.Mol Ther Methods Clin Dev. 2018; 11: 9-28
- Genome-wide target specificities of CRISPR RNA-guided programmable deaminases.Nat Biotechnol. 2017; 35: 475-480
- Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.Annu Rev Biochem. 2019; 88: 191-220
- Unbiased investigation of specificities of prime editing systems in human cells.Nucleic Acids Res. 2020; 48: 10576-10589
- Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases.Nat Rev Genet. 2016; 17: 300-312
- Illuminating the genome-wide activity of genome editors for safe and effective therapeutics.Genome Biol. 2018; 19: 226
- Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.Nat Genet. 2021; 53: 895-905
- Cas9 activates the p53 pathway and selects for p53-inactivating mutations.Nat Genet. 2020; 52: 662-668
- CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.Nat Med. 2018; 24: 927-930
- p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells.Nat Med. 2018; 24: 939-946
- Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements.Nat Biotechnol. 2018; 36: 765-771
- Gene editing and genotoxicity: targeting the off-targets.Front Genome Ed. 2020; 2: 613252
- Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors.Nature. 2019; 569: 433-437
- Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis.Nature. 2019; 571: 275-278
- Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors.Nat Biotechnol. 2020; 38: 620-628
- Current Status and Challenges of DNA Base Editing Tools.Mol Ther. 2020; 28: 1938-1952
- Genome-wide target specificity of CRISPR RNA-guided adenine base editors.Nat Biotechnol. 2019; 37: 430-435
- Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity.Nat Commun. 2020; 11https://doi.org/10.1038/s41467-020-15887-5
- A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects.Nat Methods. 2020; 17: 600-604
- AcrIIA5 suppresses base editors and reduces their off-target effects.Cells. 2020; 9: 1786
- CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.Nat Commun. 2020; 11: 4132
- Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.Cells. 2020; 9: 1608
- Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity.Nat Biotechnol. 2020; 38: 883-891
- Betibeglogene Autotemcel for Beta Thalassemia: Effectiveness and Value; Evidence Report.Institute for Clinical and Economic Review, 2022 (Available at:) (Accessed June 2, 2022)
- The chemokine GROβ mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment.Blood. 2007; 110: 860-869
- Rapid Mobilization Reveals a Highly Engraftable Hematopoietic.Stem Cell. Cell. 2018; 172: 191-204.e10
- Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.Nat Commun. 2019; 10: 617
- Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.Nat Biotechnol. 2016; 34: 738-745
- Lipid Nanoparticle Systems for Enabling Gene Therapies.Mol Ther. 2017; 25: 1467-1475
- Therapeutic in vivo delivery of gene editing agents.Cell. 2022; 185: 2806-2827
- Ensuring a future for gene therapy for rare diseases.Nat Med. 2022; 28: 1985-1988
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
